Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non‐neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society
Enzo Errichetti(University of Udine), Aimilios Lallas(Aristotle University of Thessaloniki), Rainer Hofmann‐Wellenhof(Medical University of Graz), Ružica Jurakić Tončić(University of Zagreb), Caterina Longo(Istituto Giannina Gaslini), D. Ioannides(Hospital Venereal and Skin Diseases Thessaloniki), A. Hallpern(Memorial Sloan Kettering Cancer Center), Harold Rabinovitz(Pontificia Universidad Católica de Chile), Elvira Moscarella(University of Campania "Luigi Vanvitelli"), H. Peter Soyer(The University of Queensland), Ralph P. Braun, Philipp Tschandl(Simon Fraser University), Elizabeth Lazaridou(Papageorgiou General Hospital), Josep Malvehy(Universitat de Barcelona), W. Stolz(München Klinik), Masaru Tanaka, Lidia Rudnicka(Medical University of Warsaw), Scott W. Menzies(Royal Prince Alfred Hospital), Francesco Lacarrubba(University of Catania), Alon Scope(Memorial Sloan Kettering Cancer Center), Giuseppe Argenziano(Regione Campania), Renato Marchiori Bakos(Universidade Federal do Rio Grande do Sul), Giuseppe Stinco(Unknown), Chryssoula Papageorgiou(Aristotle University of Thessaloniki), Susana Puig(Instituto de Salud Carlos III), Giuseppe Micali(University of Catania), L. Thomas(University of Liverpool), Zoé Apalla(Aristotle University of Thessaloniki), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Efstratios Vakirlis(Aristotle University of Thessaloniki), Ashfaq A. Marghoob(Memorial Sloan Kettering Cancer Center), Andreas Blum(Klinikum Konstanz), Teresa Russo(University of Campania "Luigi Vanvitelli"), Giovanni Pellacani(Sapienza University of Rome), Horacio Cabo, Harald Kittler(Medical University of Vienna)
Cited by 183
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC)
|arXiv (Cornell University)|2019|990
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589